Avicanna Inc. (AVCNF)
| Market Cap | 21.55M |
| Revenue (ttm) | 17.63M |
| Net Income (ttm) | -1.76M |
| Shares Out | n/a |
| EPS (ttm) | -0.02 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 200 |
| Average Volume | 18,375 |
| Open | 0.1931 |
| Previous Close | 0.1900 |
| Day's Range | 0.1845 - 0.1976 |
| 52-Week Range | 0.1150 - 0.3762 |
| Beta | 0.33 |
| RSI | 51.77 |
| Earnings Date | Aug 14, 2025 |
About Avicanna
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets worldwide. The company commercializes approximately thirty proprietary evidence-based finished products. It provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios of cannabinoids under the RHO Phyto brand; and indication-specific... [Read more]
Full Company ProfileFinancial Performance
In 2024, Avicanna's revenue was 25.46 million, an increase of 51.62% compared to the previous year's 16.79 million. Losses were -3.62 million, -58.62% less than in 2023.
Financial numbers in CAD Financial StatementsNews
Avicanna Announces Sponsorship of Pilot Phase II Clinical Study Osteoarthritis Pain
Multi-centre, blinded, randomized placebo-controlled investigator initiated study, to be led by Dr. Hance Clarke and conducted at University Health Network Multi-centre, blinded, randomized placebo-co...
Avicanna Reports Q1 2025 Results and First Profitable Quarter
TORONTO, May 15, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and co...
Avicanna Inc. (AVCNF) Q4 2024 Earnings Call Transcript
Avicanna Inc. (OTCQX:AVCNF) Q4 2024 Earnings Call April 22, 2025 8:30 AM ET Company Participants Aras Azadian - Chief Executive Officer Phil Cardella - Chief Financial Officer Conference Call Particip...
Avicanna Announces Revocation of Management Cease Trade Order
TORONTO, April 16, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and co...
Avicanna Reports Full Year 2024 Audited Financial Statement
2024 Revenue of $25.5M, a 52% increase from 2023 Consolidated Gross Margins of 51%, Gross Profits of $12.9M, a 94% increase from 2023
Avicanna Announces Receipt of Management Cease Trade Order and Provides Bi-Weekly Status Update
Auditor Licensing & Personnel Issues Delays Issuance of Audit Opinion The Company expects to file within 1 week
Avicanna Announces its 5th Medical Symposium on Cannabinoid-based Medicine
Bridging Science and Clinical Practice: A Gathering of Thought Leaders in Cannabinoid Medicine Live and Virtual Symposium on June 6 th , 2025, at the MaRS Discovery District, Toronto
Avicanna Announces Late Filing of Financial Statements and Application for Management Cease Trade Order
Auditor Licensing & Personnel Issues Delays Issuance of Audit Opinion The Company expects to file within 2 weeks
Avicanna To Hold Full Year 2024 Earnings Conference Call
TORONTO, March 18, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and co...
Avicanna Announces Scientific and Medical Affairs Collaboration with Vectura Fertin Pharma
Collaboration aims to facilitate research and medical affairs initiatives related to medical cannabis in Canada Collaboration aims to facilitate research and medical affairs initiatives related to med...
Avicanna Completes First Delivery of Proprietary Topical Products to Multinational Pharmaceutical Company
Cosmetic registration and delivery into Germany completed in preparation for the initial commercial Launch Cosmetic registration and delivery into Germany completed in preparation for the initial comm...
Avicanna Reports Q3 2024
9-month revenue of $18.8 million, representing a 75% increase from 2023. Consolidated Gross Margins of 57%, during Q3 2024.
Avicanna Announces Closing of Non-Brokered Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LA...
Avicanna Announces Medical Cannabis Real World Evidence Study through MyMedi.ca
1000 patient study on impact of medical cannabis on pain, sleep, anxiety, depression, and epilepsy Study to be led by Dr. Hance Clarke President of The Canadian Pain Society and the CCIC 1000 patient ...
Avicanna Announces Repayment of Debentures
TORONTO, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the...
Avicanna Announces United States Patent and Trademark Office Issuance of Patent on Topical Technology
USPTO issues Patent No. US 20230025693A1 (“ Patent ”) that covers Avicanna's deep penetrating topical cannabinoid composition and methods for treating musculoskeletal inflammation and pain
Avicanna Subsidiary Completes Export of Aureus Branded CBG into Denmark
19th international market for Aureus branded products and 22nd market for all Avicanna products 19th international market for Aureus branded products and 22nd market for all Avicanna products
Avicanna Reports Q2 2024
Q2 2024 revenue of $6.1 million an increase of 85% over Q2 2023 Completion of two real world evidence trials on Epidermolysis Bullosa and Musculoskeletal Pain
Avicanna Announces Changes of Auditors
TORONTO, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and c...
Avicanna Subsidiary Completes Export of Aureus Branded CBG into Singapore
This marks the first export into Asia, the 18 th international market for Aureus branded products and 21 st market for all Avicanna products
Avicanna Announces Results of Annual General Meeting & Provides Corporate Update
TORONTO, July 10, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and ...
Avicanna General Meeting
TORONTO, June 19, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and c...
Avicanna Announces USPTO Issuance of Patent SEDDS Technology
Patent No. US 11,998,632 B2 (“Patent”) covers Avicanna's self-emulsifying drug delivery system (“SEDDS”) oral cannabinoid composition and methods of treating neuropathic pain Patent No. US 11,998,632 ...
Avicanna to Present at the Life Science Investor Forum June 20th, 2024
Investors, advisors and analysts, will have the opportunity to attend in-person or participate online at VirtualInvestorConferences.com Investors, advisors and analysts, will have the opportunity to a...
Avicanna Reports Q1 2024 and First Positive Adjusted EBIDTA Quarter
Best Quarterly Results in Company's History from a Financial Perspective. EBITDA Improvements Driven by Record Revenues, Record Margins and Operational Efficiencies. Marketing Authorization of Trunero...